Sarah Boyce - Jan 20, 2023 Form 4 Insider Report for Avidity Biosciences, Inc. (RNA)

Role: President and CEO, Director
Signature: /s/ John W. Wallen III, Ph.D., J.D., Attorney-in-Fact
Stock symbol: RNA
Transactions as of: Jan 20, 2023
Transactions value $: $0
Form type: 4
Date filed: 1/24/2023, 08:13 PM
Previous filing: Nov 14, 2022
Next filing: Feb 1, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RNA	Common Stock	Award	$0	+50K	+1491.65%	$0.00	53.4K	Jan 20, 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RNA	Stock Option (Right to Buy)	Award	$0	+400K		$0.00	400K	Jan 20, 2023	Common Stock	400K	$22.47	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in four equal installments on the first four anniversaries of January 20, 2023, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
F2	Includes 3,352 shares previously acquired by the Reporting Person under the Avidity Biosciences, Inc. 2020 Employee Stock Purchase Plan.
F3	1/48th of the total number of shares subject to the options shall vest on each monthly anniversary of January 20, 2023 (the "Vesting Commencement Date"), subject to the Reporting Person's continuous service to the Issuer on each such vesting date, so that the options shall be fully vested on the fourth anniversary of the Vesting Commencement Date.